OncoMatch

OncoMatch/Clinical Trials/NCT06059261

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Is NCT06059261 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Envafolimab and recombinant human endostatin combined with chemoradiotherapy for nasopharyngeal carcinoma.

Phase 2RecruitingChongqing University Cancer HospitalNCT06059261Data as of Jun 2026Location: China

Treatment: Envafolimab and recombinant human endostatin combined with chemoradiotherapyThis is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Envafolimab and recombinant human endostatin combined with chemoradiotherapy

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 65

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiotherapy

Cannot have received: systemic chemotherapy

Cannot have received: immune checkpoint inhibitor

Lab requirements

Blood counts

WBC ≥ 4000/μL, neutrophils ≥ 2.000/μL, hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/μL

Kidney function

serum creatinine < 1.5 × ULN

Liver function

ALT, AST < 1.5 times the upper limit of normal (ULN), total bilirubin < 1.5 × ULN

Hematology: WBC ≥ 4000/μL, neutrophils ≥ 2.000/μL, hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/μL; Liver function: ALT, AST < 1.5 times the upper limit of normal (ULN), total bilirubin < 1.5 × ULN; Renal function: serum creatinine < 1.5 × ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06059261 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage III or IVA is required.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify